rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    CABA
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Cabaletta Bio: Revisiting A Wrong Call

      Analyst rates Cabaletta Bio a Buy at a $276 million valuation below $299 million cash, though one IEC-HS case could drive 80% or more downside.

      Nov 16Seeking AlphaCABA
      Cabaletta Bio at guggenheim healthcare conference: safety edge in focus
      Nov 10Investing.comCABA
      Cabaletta Bio reports phase 1/2 data for autoimmune therapy
      Nov 8Investing.comCABA
      Cabaletta Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
      Nov 4Yahoo FinanceCABA
      Cabaletta Bio: 40% Sell-Off Creates an Opportunity Despite Cash Concerns

      Cabaletta Bio is rated Buy, trading 40% below its $2.41 pipeline value despite a single-asset risk profile. Click here to read this CABA stock update.

      Oct 13Seeking AlphaCABA
      H.C. Wainwright Keeps Their Buy Rating on Cabaletta Bio (CABA)

      Detailed price information for Cabaletta Bio Inc (CABA-Q) from The Globe and Mail including charting and trades.

      Sep 22The Globe and MailCABA
      Cabaletta Bio at Morgan Stanley conference: safety and scale in focus
      Sep 14Investing.comCABAMS
      Cabaletta Bio raises $128.2 million from warrant exercises ahead of expiration
      Sep 14Investing.comCABA
      Cabaletta Bio at cantorfitzgerald healthcare conference: safety and scale
      Sep 9Investing.comCABA
      Wall Street Analysts Are Bullish on Top Healthcare Picks

      Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

      Sep 3The Globe and MailCABA
      Cabaletta Bio to Participate in Upcoming Investor Conferences

      PHILADELPHIA, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on developing and launching curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced its participation in the following upcoming investor conferences: Wells Fargo 21st Annual Healthcare Conference: Meetings with investors on Tuesday, September 8, 2026, in Boston, MA.2026 Cantor Global Healthcare Conference: M

      Sep 1Yahoo FinanceCABA

      This is the newest page. Registered accounts read further back.